Cancer Research UK (CRUK) has funded a project run by a team of researchers at the University of Bristol to develop a new blood-based test for early diagnosis of brain cancer. The researchers are planning to deploy the point-of-care (POC) assay based on a fluorescent nanophotonics platform, which is a platform that studies the behaviour […]
Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.
John Hopkins University has announced a partnership with Cambridge-based start-up, Capsulomics, to study the detection of oesophageal cancer and Barrett’s oesophagus.
Scientists at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have found that drugs used for inflammation, diabetes, alcoholism, and arthritis also have anti-cancer properties. Published in Nature Cancer, this is the first study to screen an entire collection of mostly non-cancer drugs to see if they can kill cancer cells.
New research has identified a possible reason why men are more susceptible to cancer than women. The work published in the Journal of the National Cancer Institute reports that the loss of function in certain genes of the sex-determining Y chromosome may play a role in this.
Researchers from the Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) have discovered that Acute Myeloid Leukaemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The findings could pave the way for a treatment that can stop cancer growth by manipulating the enzyme that pushes B6 to make proteins essential for cell division.
A research team from Lewis Katz School of Medicine at Temple University (LKSOM) and Fox Chase Cancer Centre found that in prostate cancer, a mutation leading to the loss of just one allele of a tumour suppressor gene known as PPP2R2A is enough to make a tumour caused by other mutations worse.
Interview with Dr Susie Cooke, Head of Medical Genomics at the Glasgow Precision Oncology Laboratory
Dr Susie Cooke is the Head of Medical Genomics at the Glasgow Precision Oncology Laboratory whose main interest is in facilitating the move of next-generation sequencing into the clinic to help cancer patients.
Scientists at Navega Therapeutics in San Diego, California have discovered a way to target DNA to stop pain signals being sent and eliminate pain. In an article published by Pharmafile, the treatment could be available in five years to help sufferers of chronic pain or with long-term pain problems.
Researchers at the German Centre for Neurodegenerative Diseases (DZNE) and the University of Bonn have investigated the use of artificial intelligence to detect one of the most common forms of blood cancer – acute myeloid leukaemia (AML) – with high reliability. Published in iScience, the technique was used to analyse the expression of certain genes in cells of the blood.
Researchers at Penn Medicine have developed an imaging technique that can provide a non-invasive characterisation of tumour heterogeneity. They used Magnetic Resonance Imaging (MRI) and radiomics – an emerging field of medicine that uses algorithms to extract large amounts of features from medical images
Researchers at the Salk institute have discovered a way in which some cancers resist chemotherapy. Published in Nature Metabolism, they showed that mitochondria can signal to the rest of the cell when there is stress or chemicals that can damage DNA, such as chemotherapy.
A new non-invasive method to detect the presence of human papilloma virus (HPV)-16 in saliva has been successfully used in a collaboration between Duke University, UCLA, and University of Birmingham. HPV-16 is a high-risk virus known to be an etiologic agent for the development of head and neck cancers, specifically with oropharyngeal caners (OPCs).
The immunotherapy drug Blinatumomab has shown to be an effective treatment for children and young adults with relapsed B-cell acute lymphoblastic leukaemia in a clinical trial led by the Children’s Oncology Group, part of the National Cancer Institute USA, and presented at the annual meeting at the American Society of Haematology.
Researchers at the Wellcome Sanger Institute uncovered a possible pre-cancerous signature for Wilms’ tumour, a form of kidney cancer mainly affecting children under five years old. Published in Science, the research was the first to compare Wilms’ tumour tissue and healthy kidney tissue to identify any genetic changes that could possibly be predictive of disease progression.